Plasma adiponectin is decreased in nonalcoholic fatty liver disease

European Journal of Endocrinology

Volumn 152, Issue 1, 2005, Pages 113-118

  Pagano, Claudio ^a,b   Soardo, Giorgio ^a,b   Esposito, Walter ^a,b   Fallo, Francesco ^a,b   Basan, Lorenza ^a,b   Donnini, Debora ^a,b   Federspil, Giovanni ^a,b   Sechi, Leonardo A ^a,b   Vettor, Roberto ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMINOTRANSFERASE; LEPTIN; LIPID;

ADIPOSE TISSUE; ADULT; AGE DISTRIBUTION; AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BODY MASS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FATTY LIVER; FEMALE; GENDER; HOMEOSTASIS; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER BIOPSY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MORBIDITY; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PRIORITY JOURNAL;

ADIPONECTIN; ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CHOLESTEROL, HDL; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; MALE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 13244295710     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01821     Document Type: Article

References (26)

1. Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine 2002 346 1221-1231.
2. American Gastroenterology Association, Medical Position Statement: Nonalcoholic fatty liver disease. Gastroenterology 2002 123 1702-1704.
3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N & Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37 917-923.
4. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G & Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. American Journal of Medicine 1999 107 450-455.
5. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G & Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001 50 1844-1850.
6. Pittas AG, Joseph NA & Greenberg AS. Adipocytokines and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2004 89 447-452.
7. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R & Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003 423 762-769.
8. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS & Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. Journal of Clinical Investigation 2003 112 91-100.
9. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA & Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. American Journal of Gastroenterology 1999 94 2467-2474.
10. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW & George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003 125 1695-1704.
11. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G & Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004 126 586-597.
12. Monto A, Alonzo J, Watson JJ, Grunfeld C & Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002 36 729-736.
13. Combs TP, Berg AH, Obici S, Scherer PE & Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. Journal of Clinical Investigation 2001 108 1875-1881.
14. Stefan N, Stumvoll M, Vozarova B, Weyer C, Funahashi T, Matsuzawa Y, Bogardus C & Tataranni PA. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003 26 3315-3319.
15. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Froguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R & Kadowaki T. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. Journal of Biological Chemistry 2004 279 30817-30822.
16. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, Berria R, Belfort R, DeFronzo RA, Mandarino LJ & Ravussin E. Adiponectin receptor gene expression and insulin sensitivity in non-diabetic Mexican-Americans with or without a family history of type 2 diabetes. Diabetologia 2004 47 816-820.
17. Diehl AM. Nonalcoholic steatosis and steatohepatitis. IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. American Journal of Physiology: Gastrointestinal and Liver Physiology 2002 282 G1-G5.
18. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y & Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000 96 1723-1732.
19. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T & Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003 125 1796-1807.
20. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Pukuda T, Yamashina S, Kitamura T & Sato N. Leptin receptor-mediated signalling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002 122 399-410.
21. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK & Considine RV. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? American Journal of Gastroenterology 2003 98 2771-2776.
22. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y & DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2004 89 200-206.
23. López-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W & Manuel Fernández-Real J. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clinical Endocrinology 2004 60 256-263.
24. Tietge UJF, Boker KHW, Manns MP & Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. American Journal of Physiology: Endocrinology and Metabolism 2004 287 E82-E89.
25. English PJ, Coughlin SR, Hayden K, Malik IA & Wilding JP. Plasma adiponectin increases postprandially in obese, but not in lean, subjects. Obesity Research 2003 11 839-844.
26. Karlsson FA, Engstrom BE, Lind L & Ohrvall M. No postprandial increase of plasma adiponectin in obese subjects. Obesity Research 2004 12 1031-1032.